Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBA versus insulin glargine in a basal-bolus regimen for type 2 diabetes
2008-005777-35Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing SIBA + insulin aspart ± metformin ± pioglitazone with Insulin glargine + insulin aspart ± metformin ± pioglitazone (2 arms). Primary endpoints: Primary efficacy endpoint and Primary hypothesis framework. Started May 2009; status: completed.
02
Drugs
insulin degludecinsulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005777-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005777-35.